Skip to main content
CHEMCLIN DIAGNOSTICS CO., LTD. logo

CHEMCLIN DIAGNOSTICS CO., LTD. — Investor Relations & Filings

Ticker · 688468 ISIN · CNE100005311 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2024-04-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688468

About CHEMCLIN DIAGNOSTICS CO., LTD.

https://www.chemclin.com/

CHEMCLIN DIAGNOSTICS CO., LTD. specializes in the research, development, and manufacturing of in vitro diagnostic systems and reagents. The company is primarily recognized for its proprietary Light-initiated Chemiluminescent Assay (LiCA) technology, a homogeneous chemiluminescence platform that eliminates the need for washing steps, thereby enhancing testing efficiency and precision. Its product portfolio includes fully automated immunoassay analyzers and a comprehensive range of diagnostic kits covering infectious diseases, cardiac markers, thyroid function, tumor markers, and reproductive health. By integrating advanced biotechnology with automated instrumentation, the company provides clinical laboratories and medical institutions with high-sensitivity diagnostic solutions designed to improve patient care and laboratory workflow.

Recent filings

Filing Released Lang Actions
科美诊断技术股份有限公司关于续聘2024年度审计机构的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an audit firm (信永中和会计师事务所) for the company's 2024 audit. It details the audit firm's background, qualifications, independence, and the internal approval process by the audit committee and board of directors. It explicitly states that the appointment is subject to shareholder approval at the 2023 annual general meeting. The document does not contain any financial statements or audit reports themselves, but rather is an announcement about the audit firm appointment process. Therefore, it is not an Audit Report (AR) or Annual Report (10-K), but an announcement related to audit firm appointment, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2024-04-29 Chinese
科美诊断技术股份有限公司关于召开2023年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a notice about the convening of the 2023 Annual General Meeting (AGM) of the company 科美诊断技术股份有限公司. It includes details such as the date, location, voting methods, agenda items to be discussed and voted on, and instructions for shareholders to attend or vote. The document does not contain the actual annual report or financial statements but rather informs shareholders about the meeting where such reports will be discussed and voted upon. The document length is 3706 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document is best classified as AGM Information (AGM-R).
2024-04-29 Chinese
科美诊断技术股份有限公司2023年度利润分配方案公告
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from the company's board regarding the profit distribution plan for the fiscal year 2023. It details the dividend per share, total dividend amount, and the approval process including board and supervisory committee approvals. The document explicitly states that the profit distribution plan will be submitted to the annual general meeting for approval. There are no detailed financial statements or comprehensive financial performance data included, only the dividend distribution specifics and procedural information. The document length is short (1393 characters), and it serves as an official announcement of dividend amount and payment details to shareholders. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2024-04-29 Chinese
中信证券股份有限公司关于科美诊断技术股份有限公司使用闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the use of idle raised funds by Kemei Diagnostics Technology Co., Ltd. for cash management. It includes extensive information about the raised funds, their usage, investment purposes, risk control measures, board approvals, and the sponsor's verification opinions. The document references regulatory guidelines and approvals, and it is not a brief announcement but a substantive report with financial and procedural details. It is not an annual or interim report, nor a simple announcement or certification. The content aligns with an Audit Report / Information type, as it involves verification and audit-related opinions on the use of raised funds, consistent with regulatory compliance and internal controls. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2024
2024-04-29 Chinese
科美诊断技术股份有限公司第二届董事会第十次会议决议公告
AGM Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed by the company's board of directors during a meeting held on April 29, 2024. It includes approvals of the 2023 Annual Report, 2024 Q1 Report, various internal reports, proposals for the 2023 Annual General Meeting, and other governance matters. The document repeatedly states that the detailed reports are disclosed separately on the Shanghai Stock Exchange website and that these matters still require shareholder approval at the upcoming AGM. The document length is 3468 characters, which is relatively short and mainly summarizes board meeting decisions rather than containing the full reports themselves. This fits the pattern of a Proxy Solicitation & Information Statement (PSI) or an AGM Information document. However, since it is a board meeting announcement of resolutions to be submitted to the AGM and includes multiple agenda items for shareholder approval, it aligns best with AGM Information (AGM-R). It is not a full Annual Report (10-K) or Interim Report (IR) because it does not contain substantive financial data but references external disclosures. It is not a Regulatory Filing (RNS) because it is a formal board meeting announcement with voting results and agenda items for the AGM. Therefore, the classification is AGM Information (AGM-R).
2024-04-29 Chinese
科美诊断技术股份有限公司董事会审计委员会对会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the company's Board Audit Committee regarding the appointment and supervision of the external auditor (ShineWing Certified Public Accountants) for the 2023 fiscal year. It discusses the auditor's qualifications, audit procedures, communication with management, and the audit committee's oversight activities. The document references the 2023 annual financial report audit and internal control evaluation, and confirms that the auditor issued an unqualified opinion. The content focuses on the audit process and the audit committee's supervisory role rather than presenting the full annual report or the audit report itself. Given the focus on audit-related information and oversight, this document fits best under the category of Audit Report / Information (AR). The document length (1867 characters) is sufficient to be more than a brief announcement but does not contain the full annual report or financial statements, so it is not a 10-K or IR. It is not a simple announcement or certification, so not RNS or RPA. Therefore, the classification is AR with high confidence. FY 2023
2024-04-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.